By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A BG Medicine official said that the company has not pulled its initial public offering, despite being unable to price it thus far.

In an e-mail to GenomeWeb Daily News, Stacie Rader, senior vice president of executive operations and human resources for the firm, denied a Dow Jones Newswire article, which stated that the Waltham, Mass., biomarker development firm had abandoned its IPO because it had been unable to price it during the week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.